Legend Biotech Corporation Stock News

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB ) retreated in four out of five sessions of the week. Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off. NuCana plc. (NASDAQ: NCNA ) was among the worst decliners of the week, with the stock reacting to the stalling of the company''s Phase 3 biliary tract cancer study. SAB Biotherapeutics, Inc. (NASDAQ: SABS ) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company''s SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD ) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study. FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT ) and Gilead Sciences, Inc. (NASDAQ: GILD ) failing to get their investigational drugs across the finish line.

Here''s why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Here's why our roundtable loves Legend Biotech, Heron Therapeutics, and Pieris Pharmaceuticals.

Legend Biotech's IPO was among the Top five largest of 2020. Compared to the other four, Legend's share price has performed exceptionally well.

The treatment, Carvykti/Cilta-cel, belongs to a class of drugs known as CAR-T therapies, or chimeric antigen receptor T-cell therapies

Shares of Legend Biotech Corp. were up 8.6% in premarket trading on Tuesday, the day after the company said that the Food and Drug Administration had approved the CAR-T therapy it developed with Johnson & Johnson as a multiple myeloma treatment. J&J''s stock was down 0.8% in premarket trading on Tuesday. Legend had inked the licensing and collaboration deal with J&J back in 2017. The treatment is approved for adults with relapsed or refractory multiple myeloma who have already received four lines of treatment. The "approval of Carvykti is a pivotal moment for Legend Biotech because it is our first-ever marketing approval, but what really excites us is the drug''s potential to become an impactful therapy option for patients in need of long, treatment-free intervals," Ying Huang, Legend''s CEO and CFO, said in a news release. Legend''s stock has soared 49.8% over the past year, while the broader S&P 500 is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

The FDA has approved Legend Biotech Corporation''s (NASDAQ: LEGN ) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory multiple myeloma. The approval covers adult patients who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Legend Biotech entered into … Full story available on Benzinga.com

The U.S. Food and Drug Administration ((FDA)) approved Johnson & Johnson (JNJ) and Legend Biotech''s (LEGN) CAR-T therapy Carvykti to treat adults with relapsed or refractory…

The U.S. health regulator has approved a therapy developed by Johnson & Johnson and its China-focused partner Legend Biotech Corp to treat a type of white blood cell cancer, the U.S. healthcare company said on Monday.

The FDA has approved a new CAR-T cancer therapy developed by Janssen and Legend Biotech to treat multiple myeloma.

Legend Biotech (LEGN) has reported preliminary results for 2021, expecting loss of ~$365.3M to $397.4M and adj. loss of $335.8M to $364.7M.As of Dec

The FDA has instituted a clinical hold on Legend Biotech Corporation''s (NASDAQ: LEGN ) Phase 1 trial for LB1901. LB1901 is the company''s investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The … Full story available on Benzinga.com

Legend Biotech (LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration ((FDA)) imposed a clinical hold on its Phase…

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901.  LB1901 is the company's investigational autologous chimeric antigen receptor T-cel